Welcome to our dedicated page for Alpine Immune Sciences news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences stock.
Founded in 2015, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a leading clinical-stage biotechnology company dedicated to developing innovative protein-based immunotherapies to treat autoimmune and inflammatory diseases. Alpine leverages its unique understanding of immunology, particularly recombinant protein-based immunotherapies, to modify the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Alpine's standout product, povetacicept (ALPN-303), is a dual antagonist of the BAFF and APRIL cytokines. This product is currently in phase 2 development and has demonstrated potential best-in-class efficacy for treating IgA nephropathy (IgAN). IgAN is a serious, progressive kidney disease with no approved therapies that target its underlying cause. Povetacicept has exhibited promising results in reducing proteinuria, stabilizing renal function, and reducing key disease-related biomarkers.
Additionally, Alpine has a robust pipeline, including acazicolcept (ALPN-101), a first-in-class dual inhibitor targeting the CD28 and ICOS T-cell costimulatory pathways. This drug is being investigated for treating systemic lupus erythematosus (SLE) and other autoimmune diseases. Alpine's research and development capabilities are enhanced by strategic collaborations with leading global biopharmaceutical companies, propelling its efforts to create multifunctional immunotherapies that improve patients' lives.
The company has been highly productive in the past year, achieving significant milestones, such as the phase 2 study of acazicolcept in SLE, a pivotal phase 3 trial of povetacicept in IgAN planned for the second half of 2024, and successful financial activities supporting ongoing and future development projects.
Alpine Immune Sciences remains committed to innovation, with ongoing studies in various autoimmune diseases and strategic goals aligning with its mission to lead a new wave of immune therapeutics.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has initiated patient enrollment in the RUBY-3 study for autoimmune glomerulonephritis and plans to start the RUBY-4 study for autoimmune cytopenias in Q2 2023. The company expects initial data from both studies by the end of 2023. Financially, Alpine reported a net loss of $57.8 million for 2022, with cash reserves of $273.4 million sufficient to fund operations through 2025. Research expenses rose to $18.8 million, reflecting increased headcount for clinical programs. Collaboration revenue decreased to $2.8 million in Q4 2022, down from $4.5 million in Q4 2021.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present posters on March 22 and March 31, 2023, at the ASCPT Annual Meeting and ISN World Congress of Nephrology, respectively. The presentations will cover the early clinical pharmacokinetics of Povetacicept (ALPN-303), a dual BAFF/APRIL antagonist targeting autoimmune and inflammatory diseases. The RUBY-1 Phase 1 Study has shown that Povetacicept is well tolerated at doses up to 960 mg, with promising pharmacokinetics and effects on immunoglobulins, supporting further clinical developments.
On March 18, 2023, Alpine Immune Sciences (NASDAQ: ALPN) will present clinical data from the RUBY-1 Phase 1 study of povetacicept at the American Academy of Dermatology Annual Meeting. The study focuses on the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a dual B cell cytokine antagonist targeting autoimmune blistering diseases. Results indicate that povetacicept is well tolerated at doses up to 960 mg, demonstrating dose-dependent pharmacokinetics and significant reductions in immunoglobulins. This paves the way for future clinical advancements.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced it will release its fourth quarter and full year 2022 financial results on March 23, 2023, after market close. A corresponding conference call and webcast is scheduled for 4:30 p.m. ET the same day. The company focuses on developing innovative immunotherapies for autoimmune and inflammatory diseases, supported by a robust R&D platform and strategic collaborations with leading biopharmaceutical firms. More details can be found on the investor relations section of their website.
Alpine Immune Sciences (NASDAQ: ALPN) will participate in two healthcare conferences this March. On March 7, at 10:30 AM ET, the company will join a corporate panel on autoimmune diseases during the Cowen Healthcare Conference. Following this, on March 14, at 3:20 PM ET, Alpine will engage in a fireside chat at the Oppenheimer Healthcare Conference. Live webcasts of both events will be accessible on the company's investor relations website, with replays available for 90 days afterward. This participation underscores Alpine's commitment to developing innovative treatments for autoimmune and inflammatory diseases.
Alpine Immune Sciences (NASDAQ: ALPN) announced its participation in the SVB Securities Global Biopharma Conference on February 16, 2023, at 12:00 p.m. ET. The company will present a corporate overview and host investor meetings. A live webcast will be accessible through the investor relations section of their website, with a 90-day replay afterward. Alpine focuses on developing innovative immunotherapies for autoimmune and inflammatory diseases, leveraging advanced protein engineering technologies. The company aims to create best-in-class multifunctional therapies and has formed strategic collaborations for its clinical and preclinical pipeline.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 12:35 p.m. ET. The event will feature a fireside chat, and a live webcast will be accessible in the investor relations section of the company's website. A replay will also be available for 90 days post-event. Alpine is dedicated to innovative immunotherapy development and has a diverse pipeline of clinical candidates, alongside strategic collaborations with leading biopharmaceutical companies.
FAQ
What is the current stock price of Alpine Immune Sciences (ALPN)?
What is the market cap of Alpine Immune Sciences (ALPN)?
What does Alpine Immune Sciences, Inc. specialize in?
What is povetacicept (ALPN-303)?
What are the core focus areas of Alpine Immune Sciences?
What recent achievement has Alpine Immune Sciences accomplished?
What is acazicolcept (ALPN-101)?
What collaborations has Alpine Immune Sciences engaged in?
What is the ticker symbol for Alpine Immune Sciences?
When was Alpine Immune Sciences founded?
What is the mission of Alpine Immune Sciences?
Where can more information about Alpine Immune Sciences be found?
